Polycythemia vera and other primary polycythemias

Current Opinion in Hematology

Volumn 12, Issue 2, 2005, Pages 112-116

  Prchal, Josef T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Congenital polycythemias; Genome wide screening; Polycythemia vera

Indexed keywords

ERYTHROPOIETIN;

BLOOD LEVEL; CHROMOSOME POLYMORPHISM; CLONAL VARIATION; DIFFERENTIAL DIAGNOSIS; ERYTHROID PRECURSOR CELL; ERYTHROPOIESIS; GENE LOCATION; HUMAN; HYPOXIA; MOLECULAR BIOLOGY; NEUTROPHIL; PATHOGENESIS; POLYCYTHEMIA; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; X CHROMOSOME;

ANOXIA; DIAGNOSIS, DIFFERENTIAL; HUMANS; MUTATION; POLYCYTHEMIA; POLYCYTHEMIA VERA;

EID: 14644441737     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.moh.0000154029.05396.d2     Document Type: Review

References (53)

1. Prchal JT. Classification and molecular biology of polycythemias (erythrocytoses) and thrombocytosis. Hematol Oncol Clin North Am 2003; 17:1151-1158.
2. Kutti J, Ridell B. Epidemiology of the myeloproliferative disorders: essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis. Pathol Biol 2002; 49:164-166.
3. Bunn HF, Poyton RO. Oxygen sensing and molecular adaptation to hypoxia. Physiol Rev 1996; 76:839-885.
4. Krantz SB. Erythropoietin. Blood 1991; 77:419-434.
5. Semenza GL, Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 1992; 12:5447-5454.
6. Semenza GL, Roth PH, Fang HM, Wang GL. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor. J Biol Chem 1994; 269:23757-23763.
7. Semenza GL, Jiang BH, Leung SW, et al. Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor. J Biol Chem 1996;271:32529-32537.
8. Wiener CM, Booth G, Semenza GL. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem Biophys Res Commun 1996; 225:479-488.
9. 2 tension. Proc Natl Acad Sci USA 1995; 92:5510-5514.
10. Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev 2000; 14:1983-1991.
11. Sutter CH, Laughner E, Semenza GL. Hypoxia-inducible factor 1α protein expression is controlled by oxygen-regulated ubiquitination that is disrupted by deletions and missense mutations. Proc Natl Acad Sci USA 1995; 97:4748-4753.
12. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-275.
13. 2 sensing. Science 2001;292:464-468.
14. 2-regulated prolyl hydroxylation. Science 2001; 292:449-451.
15. Epstein AC, Gleadle JM, McNeill LA, et al. EGL-9 and mammalian homologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 2001; 107:43-54.
16. Cockman ME, Masson N, Mole DR, et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J Biol Chem 2000; 275:25733-25741.
17. Ohh M, Park CW, Ivan M, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2:423-427.
18. Tanimoto K, Makino Y, Pereira T, Poellinger L. Mechanism of regulation of the hypoxia-inducible factor-1α by the von Hippel-Lindau tumor suppressor protein. EMBO J 2000; 19:4298-4309.
19. Poliakova LA. Familial erythrocytosis among the residents of the Chuvash ASSR [published in Russian only]. Probl Gematol Pereliv Krovi 1974; 19:30-33.
20. Ang SO, Chen H, Gordeuk VR, et al. Endemic polycythemia in Russia: mutation in the VHL gene. Blood Cells Mol Dis 2002a; 28:57.
21. Ang SO, Chen H, Hirota K, et al. Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia. Nat Genet 2002b; 32:614-621.
22. Gordeuk VR, Stockton DW, Prchal JT. Congenital polycythemias/ erythrocytoses. Haematologica 2005;90:109-116. Current update of VHL polycythemia-causing mutations in the context of other polycythemic states.
23. Liu E, Percy MJ, Amos CI, et al. The worldwide distribution of the VHL 598C>T mutation indicates a single founding event. Blood 2004; 103:1937-1949. Demonstration of a single founder for Chuvash VHL VHL 598C>T mutation.
24. Cario H, Schwarz K, Jorch N, et al. Mutations in the von-Hippel-Lindau (vHL) tumor suppressor gene and vHL-haplotype analysis in patients with presumable congenital erythrocytosis. Haematologica 2005;90:19-24.
25. Gordeuk VR, Sergueeva AI, Miasnikova GY, et al. Congenital disorder of oxygen-sensing: association of the homozygous Chuvash polycythemia VHL mutation with thrombosis and vascular abnormalities but not tumors. Blood 2004; 103:3924-3932. The first controlled analysis of the phenotype, complications, and survival of Chuvash polycythemia.
26. Luttun A, Carmeliet P. Soluble VEGF receptor Flt1: the elusive preeclampsia factor discovered? J Clin Invest 2003; 111:600-602.
27. Cramer T, Yamanishi Y, Clausen BE, et al. HIF-1alpha is essential for myeloid cell-mediated inflammation [erratum appears in Cell 2003; 113:419]. Cell 2003; 112:645-657.
28. Divoky V, Liu Z, Ryan TM, et al. Mouse model of congenital polycythemia: Homologous replacement of murine gene by mutant human erythropoietin receptor gene. Proc Natl Acad Sci USA 2001; 98:986-991.
29. Beutler E, Collins Z, Irwin LE. Value of genetic variants of glucose-6-phosphate dehydrogenase in tracing the origin of malignant tumors. N Engl J Med 1967; 276:389-397.
30. Knudson AG Jr, Strong LC. Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet 1972; 24:514-532.
31. Vogelstein B, Fearon ER, Hamilton SR, Feinberg AP. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Science 1985; 227:642-645.
32. Liu EL, Jelinek JJ, Pastore YD, et al. Discrimination of polycythemias and thrombocytoses by novel, simple, accurate clonality assays and comparison with PRV-1 expression and EEC assay. Blood 2003; 101:3294-3301. Analysis of relative values of erythroid colonies, clonality, and PRV-1 in differential diagnosis of polycythemia vera.
33. Prchal JT, Prchal JF, Barany F, Guan YL. Transcriptional analysis of the active X-chromosome in normal and clonal hematopoiesis. Blood 1993; 81:269-271.
34. Prchal JT, Guan YL. A novel clonality assay based on transcriptional analysis of the active X chromosome. Stem Cells 1993; 11:62-65.
35. Gregg XT, Liu Y, Prchal JT, et al. Clonality in myeloproliferative disorders. Blood 1996; 88 (suppl):1905a.
36. Phelan JT, Prchal JT. Clonality studies in cancer based on X chromosome inactivation phenomena in molecular analysis of cancer. In: Jacqueline Boultwood, Carrie Fidler, editors. Totowa; Humana Press: 2001. pp 251-270.
37. Najfeld V, Montella L, Scalise A, Fruchtman S. Exploring polycythaemia vera with fluorescence in situ hybridization: additional cryptic 9p is the most frequent abnormality detected. Br J Haematol 2002; 119:558-566.
38. Bench AJ, Nacheva EP, Champion KM, Green AR. Molecular genetics and cytogenetics of myeloproliferative disorders. Baillieres Clin Haematol 1998; 11:819-848.
39. Li J, Bench AJ, Vassiliou GS, et al. Imprinting of the human L3MBTL gene, a polycomb family member located in a region of chromosome 20 deleted in human myeloid malignancies. Proc Natl Acad Sci USA 2004; 101:7341-7346. Demonstration of imprinted locus in the commonly deleted chromosomal region in polycythemia vera patients.
40. Temerinac S, Klippel S, Strunck E, et al. Use of restriction fragment length polymorphisms to determine the clonal origin of human tumors. Blood 2000; 95:2569-2576.
41. Klippel S, Strunck E, Busse CE, et al. Biochemical characterization of PRV-1, a novel hematopoietic cell surface receptor, which is overexpressed in polycythemia rubra vera. Blood 2002; 100:2441-2448.
42. Kralovics R, Sokol L, Prchal JF, Prchal JT. Identification of putative molecular lesion of polycythemia vera phenotype. Blood 1995; 86:1066a.
43. Moliterno AR, Hankins WD, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998; 338:572-580.
44. Kralovics R, Guan Y, Prchal JT. Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Exp Hematol 2002; 30:229-236.
45. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood first edition on line May 22, 2003:101a. The rigorous description and genetic study of familial predisposition for polycythemia vera diagnosis.
46. Weinberg R. In vitro erythropoiesis in polycythemia vera and other myeloproliferative disorders. Semin Hematol 1997; 34:64-69.
47. Kralovics R, Buser AS, Teo SS, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003; 102:1869-1871. Confirmation of the specificity of erythroid colonies in the diagnosis of polycythemia vera, and non-specificity of PRV-1 test, and demonstration of lack of specificity of c-mpl and 9 p LOH defect in polycythemia vera diagnosis.
48. Birgegard G, Wide L. Serum erythropoietin in the diagnosis of polycythemia vera. Br J Haematol 1992; 81:603-606.
49. Messinezy M, Westwood NB, El-Hemaidi I, et al. Serum erythropoietin values in erythrocytoses and in thrombocythemia. Br J Haematol 2002; 117:47053.
50. Mossuz P, Girodon F, Donnard M, et al. Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis. Haematologica 2004; 89:1194-1198. The current comprehensive analysis of the value of erythropoietin assay in differential diagnosis of polycythemia.
51. Tefferi A, Lasho TL, Wolansky AP, Mesa RA. Neutrophil PRV-1 expression across the chronic myeloproliferative disorders and in secondary or spurious polycythemia. Blood 2004; 103:3547-3548.
52. Prchal JT, Prchal JF, Belickova M, et al. Clonal stability analysis of all blood lineages indicated by X-chromosomal transcriptional polymorphism. J Exp Med 1996; 183:748-760.
53. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004; 350:114-124. The largest and the most detailed prospective clinical analyses of polycythemia vera; the benefits of low dose of aspirin are established.